REPL Stock Forecast: Replimune Group, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Replimune Group, Inc. hold a median 12-month price target of $27 — +41.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 63 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Replimune Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (88): The shares have been drifting up relative to others.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
REPL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on REPL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +41.6% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Piper Sandler | Maintains | Overweight | $14 → $27 |
| 29 Oct 2026 | Leerink Partners | Maintains | Outperform | $19 → $31 |
| 26 Aug 2026 | JP Morgan | Maintains | Overweight | $20 → $21 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $17 → $20 |
| 7 Aug 2026 | Wedbush | Upgrade | Outperform | $12 → $19 |
| 4 Aug 2026 | Leerink Partners | Upgrade | Outperform | $11 → $17 |
| 31 July 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 31 July 2026 | Wedbush | Maintains | Neutral | $9.00 → $12 |
| 30 June 2026 | Wedbush | Maintains | Neutral | $6.00 → $9.00 |
| 26 June 2026 | JP Morgan | Upgrade | Overweight | — |
| 1 June 2026 | Wedbush | Maintains | Neutral | — |
| 29 May 2026 | JP Morgan | Upgrade | Neutral | — |
| 13 Apr 2026 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 13 Apr 2026 | HC Wainwright & Co. | Downgrade | Sell | — |
| 13 Apr 2026 | Jefferies | Downgrade | Hold | — |
| 13 Apr 2026 | JP Morgan | Downgrade | Underweight | — |
| 13 Apr 2026 | Leerink Partners | Downgrade | Market Perform | — |
| 13 Apr 2026 | Wedbush | Downgrade | Neutral | — |
| 5 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 4 Feb 2026 | Wedbush | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for REPL.
This page is one stock. Monday covers all of them.
REPL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
REPL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Replimune Group, Inc. returned +111.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
REPL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 8.8×
- EV / EBITDA
- —
Cheaper than 9% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −115.8%
- Return on assets
- −43.9%
- Dividend yield
- —
Higher than 12% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Replimune Group, Inc. has a market value of $1.8B and an enterprise value of $1.6B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$297.0M.
Free cash flow in the twelve months to 30 June 2026: −$280.5M.
Replimune Group, Inc. employs 465 people.
Data provided by Twelve Data
REPL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at REPL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Replimune Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about REPL
What is the REPL stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Replimune Group, Inc. have a median 12-month price target of $27, with estimates ranging from $19 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is REPL stock a buy right now?
Of the 8 analysts covering Replimune Group, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Replimune Group, Inc. 63 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank REPL?
As at 21 Nov 2026, Replimune Group, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).
Will REPL stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +41.6% from the last close, and Ticker Nerd's factor model ranks Replimune Group, Inc. 63 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the REPL stock forecast for 2030?
No analyst covering Replimune Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REPL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $31 over the next 12 months.
How has REPL stock performed over the past year?
Replimune Group, Inc. returned +111.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Replimune Group, Inc. do?
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors.
About Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors. The company’s product pipeline includes therapies built on its proprietary RPx platform, with candidates aimed at multiple cancer settings. Replimune Group, Inc. serves the oncology market by advancing biologic approaches intended to complement or expand existing cancer treatment options. Headquartered in Woburn, Massachusetts, and founded in 2015, the company operates in the United States and the United Kingdom, with an emphasis on research, development, and commercialization of cancer immunotherapy programs.
CEO Dr. Sushil Patel Ph.D. · 465 employees · United States · https://www.replimune.com